LUHUA WANG to Thrombocytopenia
This is a "connection" page, showing publications LUHUA WANG has written about Thrombocytopenia.
Connection Strength
0.652
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Score: 0.563
-
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45.
Score: 0.089